CRIS
CurisFDocument history
Earnings documents stored for CRIS.
Investor releaseQuarter not tagged2026-05-13Curis Inc (CRIS) Q1 2026 Earnings Call Highlights: Progress in Lymphoma Study and Financial ...
GuruFocus.com
Curis Inc (CRIS) Q1 2026 Earnings Call Highlights: Progress in Lymphoma Study and Financial ...
This article first appeared on GuruFocus. Release Date: May 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Curis Inc (NASDAQ:CRIS) is making steady progress in its Teykain lymphoma study, which targets a rare and difficult-to-treat NHL subtype. The company anticipates accelerated submissions for its study in both the U.S. and Europe after collaborative discussions with FDA and EMA. Curis Inc (NASDAQ:CRIS) is exploring the potential of emivusertib to change the treatment paradigm for CLL patients, aiming for deeper responses and complete remission. Initial clinical data in gastric and esophageal cancer showed a manageable toxicity profile and encouraging preliminary results. The company has sufficient cash and cash equivalents to fund planned operations into the second half of 2027. Curis Inc (NASDAQ:CRIS) reported a net loss of $24.2 million for the first quarter of 2026, a significant increase from the previous year. The increase in net loss was primarily due to a change in fair value of warrant liabilities associated with recent financing. Enrollment in the PCNSL study is described as 'lumpy,' indicating potential challenges in patient recruitment. General and administrative expenses increased due to expenses associated with recent financing activities. The company is not currently pursuing commercial partnerships for its AML program, which could limit future growth opportunities. Warning! GuruFocus has detected 5 Warning Signs with CRIS. Is CRIS fairly valued? Test your thesis with our free DCF calculator. Q: Regarding the CLL study, you guided to announcing dosing of the first five patients by mid-year. Can you provide an update on how many patients have been dosed so far and the current pace of site activation and enrollment? A: We are confident that we are on track with our target. The process of getting our sites up and running and having patients consented into the study is progressing well. We look forward to providing an update mid-summer. - Jim Dentzer, CEO Q: For the PCNSL study, will the update in the first half of 2027 be related to data or just enrollment status? A: We expect to be fully enrolled in the study by 2027, and we anticipate providing a substantial update on enrollment in the first half of 2027. We are cautiously optimistic that we are on track. - Jim Dentzer, CEO Q: Are...
Investor releaseQuarter not tagged2026-05-13Curis, Inc. Q1 2026 Earnings Call Summary
Moby
Curis, Inc. Q1 2026 Earnings Call Summary
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management is focusing on emavusertib as a potential paradigm-shifting treatment for B-cell malignancies by targeting the TLR pathway to inhibit NF-kappaB activation. The TakeAim Lymphoma study in primary CNS lymphoma (PCNSL) is designed as a single-arm registrational study following collaborative discussions with the FDA and EMA for accelerated approval pathways. Strategic expansion into Chronic Lymphocytic Leukemia (CLL) aims to address the limitations of current BTK inhibitor standards of care, which typically achieve only partial responses. The 'dual blockade' strategy combines emavusertib with BTK inhibitors to target two distinct biologic pathways, aiming for complete remission and time-limited treatment rather than lifelong chronic therapy. Management attributes the increased net loss primarily to non-cash fair value adjustments of warrant liabilities from the January 2026 PIPE financing rather than operational overspending. Operational efficiency is reflected in decreased R&D expenses, driven by lower employee-related and manufacturing costs during the quarter. Dosing of the initial five patients in the TakeAim CLL combination study with zanubrutinib is anticipated by mid-2026, with initial data expected in December. Updated clinical data from the TakeAim Lymphoma combination study in relapsed/refractory PCNSL is projected for the first half of 2027. Management expects to be in a position to be fully enrolled in the PCNSL registrational study during 2027, despite the 'lumpy' nature of ultra-orphan patient recruitment. Cash runway is projected into the second half of 2027, contingent upon the exercise of Series B warrants triggered by the public announcement of the fifth CLL patient dosing. Future regulatory submissions for emavusertib will include data for both 100mg and 200mg doses to satisfy Project Optimus requirements. The net loss of $24.2 million was significantly impacted by the change in fair value of warrant liabilities associated with the January 2026 PIPE financing. Patient recruitment for PCNSL remains a challenge due to the ultra-orphan nature of the disease, leading to inconsistent monthly enrollment patterns. The company is currently prioritizing its existing resources on PCNSL and CLL...
Investor releaseQuarter not tagged2026-05-13Curis: Q1 Earnings Snapshot
Associated Press
Curis: Q1 Earnings Snapshot
LEXINGTON, Mass. (AP) — LEXINGTON, Mass. (AP) — Curis Inc. (CRIS) on Tuesday reported a loss of $24.2 million in its first quarter. The Lexington, Massachusetts-based company said it had a loss of $1.25 per share. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CRIS at https://www.zacks.com/ap/CRIS
Investor releaseQuarter not tagged2026-05-13Curis Provides First Quarter 2026 Business Update
PR Newswire
Curis Provides First Quarter 2026 Business Update
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., May 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended March 31, 2026. Operational Highlights TakeAim Lymphoma Emavusertib is currently undergoing testing in combination with the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib in the TakeAim Lymphoma Phase 1/2 open-label, single arm expansion trial in patients with Relapsed or Refractory (R/R) Primary CNS Lymphoma (PCNSL) (CA-4948-101, NCT03328078). Patient enrollment in this study is currently ongoing. As a result of discussions with FDA and EMA, the ongoing phase 1/2 study is intended to support filings for accelerated approval of emavusertib in PCNSL in the US and Europe. Emavusertib has been granted orphan drug designation by both FDA and EMA in PCNSL. TakeAim CLL Emavusertib is also being tested in the recently initiated open label TakeAim CLL Phase 2 clinical trial of emavusertib in combination with the BTKi zanubrutinib in patients with Chronic Lymphocytic Leukemia (CLL) (CA-4948-203, NCT07271667). The goal of combining emavusertib with a BTKi is to enable a dual blockade of NF-kB, a key driver of disease in CLL and NHL, by inhibiting both the TLR and BCR pathways. The current standard of care is the use of BTK inhibitors, which block the BCR pathway and can deliver high response rates, though typically only partial responses. Previous clinical studies have shown that adding emavusertib, which blocks the TLR pathway, to a BTKi regimen can enable patients with NHL to achieve deeper responses, including complete remission or undetectable minimal residual disease (MRD) and the potential for time-limited treatment, outcomes which represent the potential for a paradigm shift in the management of CLL. Solid Tumors Dr. Patrick Grierson, Siteman Cancer Center, Washington University in St Louis, presented a poster with initial clinical data in gastric and esophageal cancer at the ASCO Gastrointestinal Cancers Symposium in January 2026. In this study, patients are treated with emavusertib in combination with FOLFOX and anti-PD1 +/- trastuzumab as first-line therapy for metastatic or unresectable gastroesophageal cance...
TranscriptFY2026 Q12026-05-12FY2026 Q1 earnings call transcript
Earnings source - 52 paragraphs
FY2026 Q1 earnings call transcript
Good afternoon, ladies and gentlemen, welcome to the Curis first quarter 2026 business update conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press zero for the operator. This call is being recorded on Tuesday, May 12th, 2026. I would now like to turn the conference over to Diantha Duvall, Chief Financial Officer. Please go ahead.
Thank you. Welcome to the Curis first quarter 2026 business update call. Before we begin, I'd like to encourage everyone to go to the investor section of our website at www.curis.com to find our first quarter 2026 business update press release and related financial tables. I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties. Actual results may differ materially. For additional details, please see our SEC filings. Joining me today on today's call are Jim Dentzer, President and Chief Executive Officer, Dr. Jonathan Zung, Chief Development Officer, and Dr. Ahmed Hamdy, Chief Medical Officer. We will also be available for a question-and-answer period at the end of the call. I'd now like to turn the call over to Jim.
Thank you, Diantha. Good afternoon, everyone, and welcome to our first quarter business update call. We continue to make steady progress in our TakeAim Lymphoma study in primary CNS lymphoma, one of the most rare and most difficult to treat of the NHL subtypes. As a reminder, the TakeAim Lymphoma study is a single-arm registrational study with an ORR endpoint that is evaluating emavusertib in combination with ibrutinib after a patient has progressed on BTKI therapy. After collaborative discussions with both FDA and EMA, we expect the study to support accelerated submissions in both the U.S. and Europe. We anticipate providing updated emavusertib clinical data from the TakeAim Lymphoma combination study with ibrutinib in patients with relapsed refractory PCNSL in the first half of 2027.
We continue to make good progress on enrollment on this registrational study and appreciate the ongoing support of our clinical investigators, key opinion leaders, and regulatory authorities. As you recall, last year, we engaged with a number of key opinion leaders who were excited and highly supportive about expanding our emavusertib studies into additional NHL subtypes. They were especially interested in exploring emavusertib's potential to fundamentally change the treatment paradigm for CLL patients, where the current standard of care is BTK inhibitors. Over the last decade, BTK inhibitors have become standard of care in CLL and NHL because of their ability to help patients achieve objective responses. However, these responses are typically partial responses, not complete remission. The result is that patients treated with a BTK inhibitor end up having to stay on it in chronic treatment for the rest of their lives.
Additionally, because they never achieve complete remission, many of these patients develop BTKI-resistant mutations, and ultimately, their disease progresses. We're looking to improve upon the current standard of care by adding emavusertib to a patient's BTKI regimen, applying a dual blockade to the two biologic pathways driving CLL. This dual blockade can enable patients whose NHL subtype partially responds to a BTK inhibitor to achieve deeper responses with the combination, including the ability to achieve complete remission or undetectable disease and the potential for time-limited treatment. If we are successful, adding emavusertib to BTKI could change the treatment paradigm in CLL, reducing the risk of developing a treatment-resisting mutation and improving a patient's overall quality of life.
The first step in testing this hypothesis in CLL is our proof-of-concept study in patients currently on BTKI monotherapy who have achieved partial remission but have been unable to achieve complete remission or undetectable MRD. We anticipate the dosing of the initial five patients in the TakeAim CLL combination study with zanubrutinib by mid-2026, and we expect to have initial data in December. In January, one of our collaborators, Dr. Patrick Grierson of the Siteman Cancer Center at Washington University in St. Louis, presented a poster with initial clinical data in gastric and esophageal cancer at the ASCO GI Cancers Symposium. In this study, patients are treated with emavusertib in combination with FOLFOX and anti-PD-1 plus or minus Herceptin as first-line therapy for metastatic or unresectable gastroesophageal cancers. The initial data showed results for 16 evaluable patients, demonstrating both a manageable toxicity profile and encouraging preliminary results.
As you can see, we had a very productive quarter and look forward to an exciting 2026 as we advance our registrational study in PCNSL and our proof of concept study in CLL. With that, I'll turn the call back over to Diantha for the financial update. Diantha?
Thank you, Jim. Curis reported a net loss of $24.2 million or $1.25 per share for the first quarter of 2026, as compared to a net loss of $10.6 million or $1.25 per share for the same period in 2025. The increase in net loss was primarily due to a change in fair value of warrant liabilities associated with the January 2026 PIPE financing. Research and development expenses were $6.4 million for the first quarter of 2026, as compared to $8.5 million for the same period in 2025. The decrease was primarily attributable to lower employee-related and manufacturing costs. General and administrative expenses were $5.1 million for the first quarter of 2026, as compared to $4.0 million for the same period in 2025.
The increase was primarily attributable to expenses associated with the January 2026 PIPE financing, partially offset by lower employee related costs. Curis' cash and cash equivalents as of March 31st, 2026, of $15 million, together with anticipated gross proceeds of up to an additional $20.2 million from the exercise of the January 2026 PIPE financing Series B warrants upon the public announcement of dosing up the fifth CLL patient in our TakeAim CLL study expected later this year, should enable the company's planned operations into the second half of 2027. With that, I'd like to open the call for questions. Operator?
Your first question comes from Sara Nik with H.C. Wainwright & Co. Please go ahead.
Hi, good afternoon, thanks for taking my question. Regarding the CLL study, you guided to announcing dosing of the first five patients by mid-year. I was wondering, if you could provide as of today, how many patients have been dosed so far, and maybe any color on the current pace of site activation and enrollment. Thank you.
Sure. Thank you, Sara. I appreciate the question, and thanks for calling in. Yeah, we're trying getting out of the realm as it is. Five is already a pretty small number. We're gonna try and get out of a patient-by-patient update. As I would say, we're obviously very, very confident that we are hitting our target on track. The process of both getting our sites up and running and our patients consented into the study is on track, and we look forward to providing an update midsummer.
Okay. Thank you.
Sure. Thank you.
Your next question comes from the Yale Jen with Laidlaw & Company. Please go ahead.
Good afternoon, and thanks for taking the questions. In terms of a PCNSL, you mentioned you're gonna have updates in the first half of 2027. Wonder that will related to the data or simply just the enrollment status or any other colors? Thanks.
Sure. Hi, Yale. Again, thanks for calling in and appreciate the question. On PCNSL, yeah, I mean, you're exactly right. What we have said is we expect that we're gonna be in a position, or at least we're hoping to be in a position where we could be fully enrolled in that study in 2027. Our expectation would be we could have a substantial update on enrollment in the first half of 2027. Right now, of course, we're a long way from that. We'll continue to provide updates as we know more going through the year. Right now, I'd say we're cautiously optimistic. We are on track, we look forward to having that discussion at that time.
Maybe just to follow up on that. In terms of the current sort of enrollment situations, I know it's a very lumpy, but overall, are they within your expectation or either better or worse, or at least at this moment? Thanks.
No, thank you. No, it's on track. You're exactly right. This is one of the issues, of course, when you're developing a drug in an ultra-orphan space. There are just, frankly, not a lot of those patients around. We will go, as we have in the past, some months where we don't have any patients, then some months where we get two or three. You know, on any given month, your description is lumpy is spot on. As we take a step back and we say, not on any given month, are we on track to hit our enrollment targets in time for a disclosure, first half of 2027? I'd say yes. We continue to see the same kind of performance over time that we have been.
Excitement continues to be very strong, as I say, we look forward to providing that update with the full data set in 2027. Stay tuned.
Okay.
We'll provide update, updated guidance as we go along through the year. Great question.
Okay, great. Thanks a lot. Again, congrats on the progress.
Thank you very much. I appreciate it.
The next question comes from Srikripa Devarakonda with Truist. Please go ahead.
Hi. This is Anna on for Kripa. Thanks so much for taking our question. Just two questions on CLL. I think you mentioned you're evaluating two doses kind of to satisfy the Project Optimus, and I know it's a small sample size, but are there any expectations for any meaningful differences in the safety profile, when you're kind of adding emavusertib to these combinations? In terms of the CLL standard of care, if you could remind us kind of how you're differentiating there. Thanks.
Yeah. Let me talk to the first part, and then I'll ask Ahmed to chime in on CLL. The first question is, yes, as part of the discussions that we had with FDA and EMA, they were very clear that we need to make sure to include data on 100 and 200 in our submissions, which of course we will do. I don't anticipate that there is a whole lot of question about safety between 100 and 200. I think as you may remember, we have dosed emavusertib as high as 500 mg. I think the safety profile should be manageable at both.
It's really a question of we know that the dose is active, at both 100 and 200, and we just need to satisfy ourselves that 200 is the best dose as a starting dose for patients and that they have the ability to dose up or down from a safety perspective as needed. Maybe diving into CLL in particular, I'll ask Dr. Hamdy to comment. Ahmed?
Sure. Thanks for the question. I think, you know, CLL, although BTKs and BCL2s have done quite a bit of difference for patients, yet the problem is patients have to continue dosing chronically for extended periods of time, leading to, you know, potential resistance and mutations, along with toxicities like cardiovascular and bleeding and bone marrow suppression, which is really one of the hardest thing for CLL patients. The treatment goal or the unmet medical need currently in CLL is getting patients to a treatment-free remission period. When we look at the current state of affairs in CLL, most patients do not achieve a CR or MRD negative, allowing them to stop treatment in a monotherapy setting.
Basically BTKs work by inhibiting the BCR signaling pathway, which would also inhibit the NF-κB, which is the driver of the disease. Because those patients are not getting to a CR or MRD negative, there's quite a bit of preclinical work that has been done by renowned key opinion leaders stating that there is a constitutive activation of the NF-κB through the TLR pathway, which emavusertib inhibits. The concept of combining emavusertib with a BTK inhibitor can potentially lead to a more profound inhibition of the NF-κB and therefore, hopefully we can see more CRs than the monotherapy or with BTK alone. We think the combo can really make a difference for those patients.
As you know, the space has also been trying to combine BTKs with BCL2s and anti-CD20s, although some of these combinations have a higher CR rate and MRD rate, yet it comes with a high toxicity profile, specifically on the bone marrow with infections and so forth. I hope we are quite differentiated from what we see right now, and as you've seen with our programs, we've combined with ibrutinib in a lot of patients, and we have not seen any additive toxicities or bone marrow suppression. We feel that this can really be a paradigm shift in the treatment of CLL in a combination setting when we inhibit two nodes in the main pathway that is activating the disease. Hope that helps.
Yep. Thanks so much.
Yeah. Thank you, Anna. Appreciate you calling in.
As a reminder, if you wish to ask a question, please press star one. We have a question from Boris Peaker with JonesTrading. Please go ahead.
Hi. Thank you for taking our questions. This is Dania for Boris. My first question is about the, as a follow-up for the CLL trial. What specific signs of activity are you looking for in the initial patients to validate this dual blockade we've been discussing?
Yeah. Again, I think that's probably a best question for Dr. Hamdy. Ahmed, if you wouldn't mind.
I'm sorry. I didn't hear clearly the last part of the question. If you mind repeating it?
Sure. Just what initial or specific signs of activity are you looking in the initial patients that you'll be enrolling?
Well, currently we're combining with zanubrutinib in patients who are currently in a PR or a PR, which is basically all zanu patients. The idea is to see deepening of responses where we can see patients inching towards a CR and getting to an undetectable MRD status, where we can get patients to a treatment-free remission by stopping both drugs.
Great. Thanks.
Yeah, let me add to that as well. In these early days, so I'll differentiate a little bit the goal where Ahmed was headed from the early days. Just as a reminder, a patient coming into the study, as Dr. Hamdy said, is currently on zanubrutinib, and they're in partial remission, meaning their CLL counts, right? They've dropped 50% or more, and then they've plateaued. They can get their cancer level down by 50%, but no lower than that or wherever they've plateaued. At that point, we enroll them in the study and add a second pill. We add emavusertib. What we really wanna see, frankly, is that we can take them from plateauing to decreasing their disease burden.
At that point, from a patient's perspective, of course, any decrease is good. We wanna see the disease trending down. From a regulatory perspective, our goal, of course, we expect to see patients with significant reductions, and we're hoping to see patients that are able to do what they can't do on monotherapy, meaning get all the way down to complete remission or MRD, and maybe even time-limited treatment. In these early days, what we're really hoping to see is a patient comes in having plateaued on zanu, and if they add a second pill, if they add emavusertib, we can see them reduce their cancer burden. That's what we're hoping. Does that make sense?
Yes. Thank you very much.
Great.
Just the last question. Are you speaking of commercial partnership for the AML program?
No, not yet. I would say at this point in time, you know, we have addressed the financing of the company with the January financing, and we appreciate that that gave us the ability to not just continue executing against PCNSL but add the PCNSL program. Right now we're focused on generating data in those indications. Of course, what we'd love to be able to do with additional resources is add AML into that same mix and take the next step, because the next step in AML would be a registrational study. You know, at some point in time, could a partnership make sense? Absolutely. We have discussions just as every biotech company does.
Right now, our goal is to use the resources from the financing that we've gained to continue to push forward, both on the registrational study and on the new study in CLL, and hopefully be able to continue the success with data that we've seen so far.
Thank you very much.
Thank you very much. Appreciate the call.
There are no further questions at this time. I will now turn the call over to Jim Dentzer for closing remarks. Please continue.
Thank you, operator, and thank you everyone for joining today's call. As always, thank you to the patients and families participating in our clinical trials, to our team at Curis for their hard work and commitment, and to our partners at Aurigene, the NCI, and the academic community for their ongoing collaboration and support. We look forward to updating you again soon. Operator?
Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.
Investor releaseQuarter not tagged2026-05-06Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
PR Newswire
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
LEXINGTON, Mass., May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its first quarter 2026 financial and operating results on Tuesday, May 12, 2026, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here or from the investor section of the Curis website. A replay of the conference call will be available at www.curis.com. About Curis, Inc. Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL). The Company's monotherapy and combination studies in acute myeloid leukemia (AML) are substantially complete, with additional funding the Company plans to continue development of emavusertib in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948). For more information, visit Curis's website at www.curis.com. View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-report-first-quarter-2026-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-12-2026-302763278.html
Investor releaseQuarter not tagged2026-04-28Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
Zacks
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +50.00%. A quarter ago, it was expected that this company would post earnings of $0.29 per share when it actually produced earnings of $0.17, delivering a surprise of -41.38%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Kiniksa Pharmaceuticals International, plc, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $214.27 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 5.24%. This compares to year-ago revenues of $137.79 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Kiniksa Pharmaceuticals International, plc shares have added about 5.7% since the beginning of the year versus the S&P 500's gain of 4.8%. While Kiniksa Pharmaceuticals International, plc has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Kiniksa Pharmaceuticals International, plc was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #5...
Investor releaseQuarter not tagged2026-03-20Curis (CRIS) Q4 2025 Earnings Call Transcript
Motley Fool
Curis (CRIS) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool. Thursday, March 19, 2026 at 4:30 p.m. ET Chief Executive Officer — James E. Dentzer Chief Financial Officer — Diantha Duvall Chief Medical Officer — Ahmed M. Hamdy Need a quote from a Motley Fool analyst? Email [email protected] James E. Dentzer: Thank you, Diantha. Good afternoon, everyone, and welcome to Curis, Inc.’s fourth quarter business update call. We continue to make steady progress in our TakeAim Lymphoma study in primary CNS lymphoma, one of the rarest and most difficult to treat of the NHL subtypes. As a reminder, the TakeAim Lymphoma study is a single-arm registrational study with an ORR endpoint that is evaluating emavusertib in combination with ibrutinib after a patient has progressed on BTKi therapy. After collaborative discussions with the FDA and EMA, we expect the study to support accelerated submissions in both the US and Europe. We continue to make good progress on enrollment in this registrational study and appreciate the ongoing support of our clinical investigators, key opinion leaders, and regulatory authorities. As you recall, last quarter we engaged with a number of KOLs who were excited and highly supportive about expanding our emavusertib studies into additional NHL subtypes. They were especially interested in exploring emavusertib’s potential to fundamentally change the treatment paradigm for CLL patients, where the current standard of care is BTKi. Over the last decade, BTK inhibitors have become the standard of care in CLL and NHL because of their ability to help patients achieve objective responses. However, these responses are typically partial responses, not complete remission. The result is that patients treated with a BTK inhibitor end up having to stay on it in chronic treatment for the rest of their lives. Additionally, because they never achieve complete remission, many of these patients develop BTKi-resistant mutations, and ultimately their disease progresses. We are looking to improve upon the current standard of care by adding emavusertib to a patient’s BTKi regimen, applying a dual blockade to the two biologic pathways driving CLL. This dual blockade can enable patients whose NHL subtype partially responds to a BTK inhibitor to achieve deeper responses with the combination, including the ability to achieve complete remission or undetectable disease and the potential for time-limited treatme...
Investor releaseQuarter not tagged2026-03-20Curis: Q4 Earnings Snapshot
Associated Press Finance
Curis: Q4 Earnings Snapshot
LEXINGTON, Mass. (AP) — LEXINGTON, Mass. (AP) — Curis Inc. (CRIS) on Thursday reported net income of $19.4 million in its fourth quarter. The Lexington, Massachusetts-based company said it had profit of $1.23 per share. Losses, adjusted for non-recurring gains, came to 50 cents per share. The drug developer posted revenue of $1.1 million in the period. For the year, the company reported a loss of $7.6 million, or 58 cents per share. Revenue was reported as $9.4 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CRIS at https://www.zacks.com/ap/CRIS
Investor releaseQuarter not tagged2026-03-20Curis, Inc. Q4 2025 Earnings Call Summary
Moby
Curis, Inc. Q4 2025 Earnings Call Summary
Management is transitioning from monotherapy to a dual-blockade strategy, combining emavusertib with BTK inhibitors to target both BCR and TLR pathways simultaneously. The strategic rationale addresses a critical gap in the current CLL standard of care, where BTKi monotherapy typically only achieves partial responses and leads to chronic treatment dependency. Performance in the AML triplet study demonstrated proof-of-concept for disease clearance, with five of eight evaluable patients achieving MRD conversion from positive to undetectable. The company is prioritizing resources toward Non-Hodgkin Lymphoma (NHL) subtypes, specifically PCNSL and CLL, due to their high unmet need and market scale respectively. Operational efficiency was improved through a reduction in R&D and G&A expenses, driven by lower manufacturing costs and streamlined employee-related expenditures. The sale of the remaining Erivedge royalty stream to Oberland was a strategic move to simplify the balance sheet and focus exclusively on the core emavusertib pipeline. The TakeAim Lymphoma study in PCNSL is designed as a single-arm registrational trial intended to support accelerated approval submissions in both the US and Europe. Initial data from the CLL proof-of-concept study is expected to be presented at the ASH Annual Meeting in December 2026. Full enrollment for the PCNSL registrational study is projected within a 12-to-18-month window, potentially enabling a regulatory filing in 2027 after six months of patient follow-up. Financial guidance indicates a cash runway into 2027, contingent on the exercise of Series B warrants triggered by the dosing of the fifth CLL patient. Future AML development is currently secondary to NHL, with further expansion dependent on securing additional capital and resource availability. A $27.2 million one-time non-cash gain was recorded in Q4 2025 following the final sale of Erivedge rights to Oberland. Management confirmed that meaningful revenue streams have effectively ended as of November 2025 following the divestment of legacy royalty interests. The company secured a PIPE financing in January 2026, providing $20.2 million in initial gross proceeds with an additional $20.2 million tied to clinical milestones. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap h...
Investor releaseQuarter not tagged2026-03-20Curis Inc (CRIS) Q4 2025 Earnings Call Highlights: A Turnaround with Strong Quarterly Profit ...
GuruFocus.com
Curis Inc (CRIS) Q4 2025 Earnings Call Highlights: A Turnaround with Strong Quarterly Profit ...
This article first appeared on GuruFocus. Net Income (Q4 2025): $19.4 million or $1.23 per share, compared to a net loss of $9.6 million or $1.25 per share in Q4 2024. Net Loss (Year Ended 2025): $7.6 million or $0.58 per share, compared to a net loss of $43.4 million or $6.88 per share in 2024. Research and Development Expenses (Q4 2025): $5.8 million, down from $9 million in Q4 2024. Research and Development Expenses (Year Ended 2025): $28.3 million, down from $38.6 million in 2024. General and Administrative Expenses (Q4 2025): $2.9 million, down from $3.4 million in Q4 2024. General and Administrative Expenses (Year Ended 2025): $14 million, down from $16.8 million in 2024. Cash and Cash Equivalents (as of Dec 31, 2025): Expected to support operations into the second half of 2027, with additional proceeds from January 2026 PIPE financing. Warning! GuruFocus has detected 4 Warning Signs with CRIS. Is CRIS fairly valued? Test your thesis with our free DCF calculator. Release Date: March 19, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Curis Inc (NASDAQ:CRIS) reported a net income of $19.4 million for the fourth quarter of 2025, a significant improvement from a net loss of $9.6 million in the same period of 2024. The company is making steady progress in its TakeAim Lymphoma study, which is expected to support accelerated submissions in both the US and Europe. Curis Inc (NASDAQ:CRIS) has begun activating clinical sites in the US and Europe for its proof-of-concept study in CLL, with initial data expected at the ASH Annual Meeting in December. The company presented promising data for its ongoing AML triplet study, with five of eight evaluable patients achieving MRD conversion. Curis Inc (NASDAQ:CRIS) has a solid financial position, with cash and cash equivalents expected to support planned operations into the second half of 2027. Curis Inc (NASDAQ:CRIS) reported a net loss of $7.6 million for the year ended December 31, 2025, despite the quarterly profit. The company will have no meaningful revenue in 2026 due to the sale of its Erivedge royalty stream to Oberland. Enrollment in the PCNSL study is challenging due to the rarity of the condition, with patient recruitment being described as 'choppy'. The company is prioritizing NHL over AML, which may delay progress in AML research and development. Cur...
Investor releaseQuarter not tagged2026-03-20Curis Provides Fourth Quarter 2025 Business Update
PR Newswire
Curis Provides Fourth Quarter 2025 Business Update
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2025. Operational Highlights TakeAim Lymphoma Lakshmi Nayak, MD, Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute in Boston, presented a poster with updated clinical data in Primary CNS Lymphoma (PCNSL) at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) in November 2025. The poster, titled Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients, showed results for 24 patients who have received treatment with emavusertib and ibrutinib, a BTK inhibitor (BTKi), for at least 1 cycle (28 days): 5 of 5 BTKi-naïve patients achieved objective response (100% ORR) 7 of 19 BTKi-experienced patients achieved objective response (37% ORR) Median treatment duration for the 12 responders was 123 days (44 – 798 days) 9 additional patients were unable to complete 1 cycle of treatment; reasons for discontinuing treatment included adverse events unrelated to treatment, disease progression, and transition to hospice care. Cecilia Merrigan, DNP, Mayo Clinic in Rochester, presented a poster with initial clinical data in Secondary CNS Lymphoma (SCNSL) at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) in November 2025. The poster, titled Promising Efficacy Signal in Secondary CNS Lymphoma Patients Treated with Emavusertib and Ibrutinib, showed results for 2 patients who had previously progressed on a BTKi. Adding emavusertib to their ibrutinib treatment resulted in 1 complete response (CR) and 1 stable disease (SD) with a 38% reduction in disease burden. Curis continues to enroll PCNSL patients in the Company's TakeAim Lymphoma study of emavusertib in combination with ibrutinib which, as a result of discussions with FDA and EMA, is intended to support filings for accelerated approval in PCNSL in the US and Europe. Emavusertib has been granted orphan drug designation by both FDA and EMA in PCNSL. TakeAim CLL Curis initiated an open label Phase 2 clinical study of emavus...